<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="94251">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02120755</url>
  </required_header>
  <id_info>
    <org_study_id>Amn-DFU-01</org_study_id>
    <nct_id>NCT02120755</nct_id>
  </id_info>
  <brief_title>A Randomized Comparison of AmnioClear™ Human Allograft Amniotic Membrane vs. Moist Wound Dressing in the Treatment of Diabetic Wounds</brief_title>
  <official_title>A Randomized Comparison of AmnioClear™ Human Allograft Amniotic Membrane vs. Moist Wound Dressing in the Treatment of Diabetic Wounds</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Liventa Bioscience</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Liventa Bioscience</source>
  <oversight_info>
    <authority>United States: Institutional Review Board</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This research project is testing a product called AmnioClear™ which is an amniotic membrane
      graft processed for Liventa Bioscience formerly AFCell Medical.  AmnioClear™ allograft human
      amniotic membrane is regulated solely under section 361 of the Public Health Service Act.

      The purpose of the study is to see if this treatment works to accelerate the healing time of
      chronic wounds.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>May 2014</start_date>
  <primary_completion_date type="Anticipated">January 2015</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Reduction in Wound Size</measure>
    <time_frame>12 Weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Clinical assessment of wound healing in terms of the reduction in size and shape of the wound over time.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Diabetic Foot Ulcers</condition>
  <condition>Wound Care</condition>
  <arm_group>
    <arm_group_label>AmnioClear™</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>AmnioClear™ Human Allograft Amniotic Membrane</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard of Care</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Standard moist wound dressing (saline wet-to-moist or a hydrogel dressing)</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>AmnioClear™ Human Allograft Amniotic Membrane</intervention_name>
    <arm_group_label>AmnioClear™</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Stable Type I or II diabetes mellitus

          -  At least one chronic diabetic ulcer

          -  Full-thickness ulcer size from 1-8 cm2.

        Exclusion Criteria:

          -  Concurrent use of corticosteroids, NSAIDs immuno-suppressive or cytotoxic agents

          -  Bleeding disorders

          -  Ulcer with muscle, tendon, capsule or bone involvement
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Duke University</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Cameron Howes</last_name>
      <email>cameron.howes@duke.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2014</verification_date>
  <lastchanged_date>April 22, 2014</lastchanged_date>
  <firstreceived_date>April 21, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Ulcer</mesh_term>
    <mesh_term>Foot Ulcer</mesh_term>
    <mesh_term>Diabetic Foot</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
